1. **A VERY DYNAMIC SECTOR**

France has more than 1,700 companies operating in the Healthtech sector: 720 Biotechs, more than 800 Medtechs and 200 specializing in digital health. By 2030, the Healthtech sector is set to generate 130,000 direct and indirect jobs and revenues of €40 billion. (France Biotech)

2. **THE BIOTECHS MAKING UP THE HEALTHTECH SECTOR**

French Biotechs devote 70% of their expenditure to R&D. Some 400 innovative products are in development, mainly in oncology, infectious diseases and the central nervous system. Enyo Pharma is currently experimenting with biomimetics to treat Hepatitis B; ImCheck is developing antibodies that stimulate the immune system in the treatment of cancer; and Abivax, winner of the European Mediscience Awards 2020, is working to fight chronic inflammatory diseases. (France Biotech; Enyo Pharma; ImCheck; Abivax)

3. **THE MEDTECHS MAKING UP THE HEALTHTECH SECTOR**

France is the second leading market in Europe for medical technologies (15%), ahead of the United Kingdom (11%). Among the most promising companies is Diabeloop, which is developing an artificial pancreas for diabetics, and Keranova, which specializes in robotic equipment for eye operations. (France Biotech; Keranova; Diabeloop)

4. **THE E-HEALTH COMPANIES MAKING UP THE HEALTHTECH SECTOR**

Valued at around €4 billion in 2020, the e-health market is increasingly important, with connected objects, biosensors, patient remote monitoring and digital diagnostic tools all currently in development. What’s more, BioSerenity produces smart clothing that can diagnose chronic diseases via a telemedicine platform and Medaviz offers an online medical teleconsultation platform. (France Biotech; BioSerenity; Medaviz)

5. **THE HEALTHTECH INVESTOR DAY PROVES A SUCCESS**

In June 2019, the first edition of the Healthtech Investor Day took place in Paris and was well received; it attracted more than 500 participants from 21 countries, with 900 meetings organized, including more than 90 European Healthtechs and investors, 60 international experts and major investment funds, including Orbimed, Temasek and Cathay capital. (HTID)
INTERNATIONAL PARTNERSHIPS

Lille-based Biotech GENFIT has signed a licensing agreement with the American company Terns Pharmaceuticals to develop and commercialize its proprietary compound elafibranor in China (GENFIT), while Innate Pharma and Britain’s AstraZeneca have entered into a co-development agreement in the field of immuno-oncology (France Biotech). Moreover, Erytech has confirmed an immune modulation partnership with American company SQZ Biotechnologies. (Erytech)

SIGNIFICANT SUPPORT FOR THE HEALTHTECH SECTOR

France has set up several support systems for innovative companies. Around nine in ten Healthtech companies benefit from the Research Tax Credit (CIR) and one in two companies are eligible for the Young Innovative Company (JEI) program. In 2018, public investment bank Bpifrance allocated €284 million to companies in the sector, split between innovation aid and equity investment. What’s more, French institutional investors have pledged €6 billion over three years to support the sector. (France Biotech)

AN INCREASINGLY IMPORTANT SECTOR

The FT120 program is a government support mechanism that fosters the development of the 120 French Tech companies most capable of becoming global technological leaders. Healthtech is the sector which comes out on top, representing nearly 20% of companies selected. Examples include Doctolib, the online medical appointments platform, and BioSerenity, which carries out medical examinations remotely and provides subsequent analysis. (French Tech)
#2 WORLDWIDE for the number of clinical trials in gene therapy and oncology

13 NOBEL PRIZES in medicine and nearly 130 cancer research projects

France is THE SECOND EUROPEAN COUNTRY to have attracted the most capital in the Healthtech sector (FRANCE BIOTECH)

#2 MARKET IN EUROPE for medical technologies (FRANCE BIOTECH; KERANOVA; DIABELOOP)

BUSINESS FRANCE
77, boulevard Saint-Jacques
75680 Paris Cedex 14
Tel.: +33 1 40 73 30 00